Tier 2 — strong

Effect of quercetin on the echocardiographic parameters of left ventricular diastolic function in patients with gout and essential hypertension

Vitalii E Kondratiuk, Yuliia P Synytsia
Wiadomosci lekarskie (Warsaw, Poland : 1960) 2018 71(8):1554-1559

Bibliography

PubMed
PMID 30684340
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignControlled adjunctive clinical study
ModelHuman intervention research
Sample84 men with gout and hypertension; 43 intervention and 41 comparison
InterventionQuercetin added to antihypertensive and urate-lowering treatment; dose not stated in abstract
Duration12 months
EndpointsBlood pressure; Uric acid

What the study showed, in plain terms

Published in 2018, this source examined uric acid and gout. Design: Controlled adjunctive clinical study. Sample/model: 84 men with gout and hypertension; 43 intervention and 41 comparison. The exposure or intervention was Quercetin added to antihypertensive and urate-lowering treatment; dose not stated in abstract. Follow-up or treatment period: 12 months.

The quercetin group showed favorable echocardiographic, urate, pressure and estimated kidney-function changes.

Randomization and masking are not established in the abstract. Concurrent treatment and surrogate endpoints limit causal and clinical conclusions.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Uric Acid and Gout: What the Trial Shows. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • The quercetin group showed favorable echocardiographic, urate, pressure and estimated kidney-function changes.
  • The recorded outcome domains were Blood pressure; Uric acid.
  • The result applies to the tested exposure: Quercetin added to antihypertensive and urate-lowering treatment; dose not stated in abstract; 12 months.

What this study can and cannot tell us

  • Randomization and masking are not established in the abstract. Concurrent treatment and surrogate endpoints limit causal and clinical conclusions.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Quercetin lowers plasma uric acid in pre-hyperuricaemic males: a randomised, double-blinded, placebo-controlled, cross-over trial
Yuanlu Shi et al. · The British journal of nutrition · 2016

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology